Startups

New York firm leads $40M Series A for Baltimore-based Dracen Pharmaceuticals

Deerfield Management Company invested $36 million in the Johns Hopkins spinout as part of the round.

Inside FastForward 1812, an East Baltimore-based incubator home that is based in East Baltimore. (Photo by Stephen Babcock)

A biotech company founded by Johns Hopkins researchers to develop new drugs to fight cancer said this week that it is raising $40 million in Series A funding.
The round for Dracen Pharmaceuticals was led by Deerfield Management Company, a New York–based firm which invested $36 million in the round.
The year-old company is building on discoveries by Johns Hopkins professors Barbara Slusher, Jonathan Powell and Rana Rais, as well as Pavel Majer of the Institute of Organic Chemistry and Biochemistry in Prague.
The research has shown initial effectiveness of “immuno-metabolism.” According to the company, this involves fighting cancer on two fronts at the same time. One element is cancer metabolism, which seeks to stop the energy sources that keep tumors alive. The other is immunotherapy, which involves harnessing the body’s own immune system to fight cancer.
The company is looking to develop a pipeline of drugs that build on this work, and also sees potential to extend to other types of diseases. The funding will help advance that work.
Deerfield’s engagement in our efforts helps bring us closer to an important potential step forward in the treatment of cancer,” Dracen CEO Thomas M. Etsok said in a statement.
It’s just the latest recent sign of interest in work at Johns Hopkins from healthcare-focused Deerfield. Separately, the firm is also backing a joint venture with Johns Hopkins for early stage therapeutic research called Bluefield Innovations. That fund has $65 million available for research work that shows promise toward being commercialized.
It’s one happening among the university’s wider effort to create more companies from research efforts that once again set the nationwide pace in spending.

Companies: Bio-Rad Laboratories

Before you go...

Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.

Our services Preferred partners The journalism fund
Engagement

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!

Trending

The person charged in the UnitedHealthcare CEO shooting had a ton of tech connections

From rejection to innovation: How I built a tool to beat AI hiring algorithms at their own game

Where are the country’s most vibrant tech and startup communities?

The looming TikTok ban doesn’t strike financial fear into the hearts of creators — it’s community they’re worried about

Technically Media